miR-197: A novel biomarker for cancers.
microRNAs (miRNAs) are small noncoding RNAs that could regulate post-transcription level through binding to 3' untranslated region (3'UTR) of target messenger RNAs (mRNAs), which were reported to be related with the incidence and development of diverse neoplasms. Among them, miR-197 was confirmed to play a vital role of oncogene or anti-oncogene in different cancers via targeting key tumorigenic or tumor-suppressive genes. Additionally, miR-197 had extensively been studied in carcinogenesis progression of cancers through various mechanisms, including apoptosis, proliferation, angiogenesis, metastasis, drug resistance and tumor suppressor, and also played a role in prognosis of cancers. In this review, we summarized the roles of miR-197 in cancers and considered it as a potentially novel biomarker for different cancers, offering an alternatively secure and effective tool in molecular targeting cancer treatment.
The First Clinical School of Nanjing Medical University, Nanjing 210009, China; The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China.
Dan-Dan
DD
Wang
The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Xiu
X
Chen
The First Clinical School of Nanjing Medical University, Nanjing 210009, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Dan-Dan
DD
Yu
The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Su-Jin
SJ
Yang
The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Hong-Yu
HY
Shen
The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Huan-Huan
HH
Sha
Center of Clinical Laboratory, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Shan-Liang
SL
Zhong
Center of Clinical Laboratory, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
Jian-Hua
JH
Zhao
Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China. Electronic address: jinhangtangjsch@163.com.
Jin-Hai
JH
Tang
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*
D014408:Biomarkers, Tumor; C546085:MIRN197 microRNA, human; D035683:MicroRNAs
Biomarker; Cancer; MicroRNA; miR-197